Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1752 • ACR Convergence 2024
T Cell-Engaging Bispecific Antibodies to Target Autoreactive 9G4 Idiotope B Cells in Systemic Lupus Erythematosus
Jin Liu¹, Yuanxuan Xia¹, Dylan Ferris¹, Elana Shaw¹, Brian Mog¹, Alexander Pearlman¹, Brock Moritz¹, Kyle J. Kaeo¹, Colin Gliech¹, Tolulope Awosika¹, Sarah DiNapoli¹, Tushar Nichakawade¹, Yang Li¹, Jiaxin Ge¹, Stephanie Glavaris¹, Nikita Marcou¹, Taha Ahmedna¹, Regina Bugrovsky², Scott A. Jenks², Chetan Bettegowda¹, Daniel Goldman³, Michelle Petri³, Iñaki Sanz⁴, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹, Suman Paul¹, Felipe Andrade⁵ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Emory University School of Medicine, Atlanta, GA, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Emory University School of Medicine, Atlanta, ⁵The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T-cell therapies hold promise for systemic lupus erythematosus (SLE) but are critically limited by scalability and long-term safety (e.g., risk of…
Abstract Number: 2203 • ACR Convergence 2024
The Association of Autoantibodies with Clinical Manifestations and Long-term Outcomes in Juvenile- and Adult-onset Systemic Sclerosis
Hideaki Tsuji¹, Ryosuke Hiwa¹, Mirei Shirakashi², Shuji Akizuki³, Ran Nakashima¹, Akira Onishi⁴, Hajime Yoshifuji¹, Masao Tanaka⁴ and Akio Morinobu⁵, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁴Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Our aim is to explore whether clinical features and long-term outcomes depend on autoantibodies in juvenile- and adult-onset systemic sclerosis (SSc), since they were…
Abstract Number: 2665 • ACR Convergence 2024
Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima¹, Atsubumi Ogawa², Motohiro Nonaka², Norimichi Nomura², Yasuhiro Nohda², Mirei Shirakashi³, Ryosuke Hiwa², Hideaki Tsuji¹, Shuji Akizuki⁴, Hajime Yoshifuji¹, Tsuneyo Mimori⁵ and Akio Morinobu⁶, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Kyoto University, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁵Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
Abstract Number: 0110 • ACR Convergence 2024
Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists
Rohan Willis¹, Vijaya Murthy², Karen Roye-Green³, Amy Thees⁴, May Choi⁵, Ken Dier⁶, Marvin Fritzler⁷, Susan Fink⁸, Vijayalakshmi Nandakumar⁹, Melissa Snyder¹⁰ and Anne Tebo¹¹, and the Association of Medical Laboratory Immunologists, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch (UTMB), League City, TX, ³University of the West Indies, Kingston, Jamaica, ⁴Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, ⁵University of Calgary, Calgary, AB, Canada, ⁶Corgenix, Broomfield, CO, ⁷Mitogen Diagnostics Corp, Calgary, AB, Canada, ⁸Clinical Immunology Laboratory, University of Washington Medical Center, Seattle, WA, ⁹ARUP/University of Utah, Salt Lake City, UT, ¹⁰Clinical Biochemistry and Immunology, Antibody Immunology Laboratory, Mayo Clinic, Rochester, MN, ¹¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: We have recently shown that anti-phospholipid (APL) assays of varying methodology demonstrate comparable analytical performance despite variable levels of agreement among individual analytes, identifying binding…
Abstract Number: 0608 • ACR Convergence 2024
Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Chau-Ching Liu⁵, Nicole Wilson⁵, Susan Manzi⁵ and Tyler O'Malley⁶, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Exagen, Vista, CA
Background/Purpose: Cell bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte C4d (BC4d) demonstrate increased diagnostic accuracy compared to conventional SLE markers (anti-dsDNA,…
Abstract Number: 0988 • ACR Convergence 2024
Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis
Yunjung Choi¹, Myeung-Su Lee² and Wan-Hee Yoo³, ¹Jeonbuk National University Medical School, Deokjin-gu, Jeollabuk-do, Republic of Korea, ²Wonkwang University Hospital, Iksan, South Korea, ³CHONBUK NATIONAL UNIVERSITY HOSPITAL, JEONJU, Republic of Korea
Background/Purpose: Cutaneous manifestations are common in rheumatic diseases and can be early indicators. This study investigates the prevalence of rheumatic diseases diagnosed through ANA (Antinuclear…
Abstract Number: 1526 • ACR Convergence 2024
Utilizing Electronic Health Records to Identify Clinical Features of ANA-Positive Patients Imparting High Risk for Progression to Systemic Lupus Erythematosus
Havell Markus¹, Chachrit Khunsriraksakul¹, Galen Foulke², Laura Carrel¹, Nancy Olsen³ and Dajiang Liu¹, ¹Penn State College of Medicine, Hershey, PA, ²Penn State Health, Hershey, PA, ³Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a severe and heterogeneous autoimmune disease. SLE is often preceded by a stage with milder symptoms and positive antinuclear…
Abstract Number: 1776 • ACR Convergence 2024
Animal Models of Pediatric MOGAD
Yike Jiang¹, Elliot Lin², Estefany Reyes², Devon DiPalma², Sundar Khadka², Heather Van Mater² and Mari Shinohara², ¹Duke Univerisity, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a devastating demyelinating disease that disproportionally affects children. Discovered in 2018, MOGAD is now internationally recognized as…
Abstract Number: 2232 • ACR Convergence 2024
Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Nicole Wilson⁵, Susan Manzi⁵, Veena Joy⁶ and Tyler O'Malley⁷, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶ThermoFisher, Philadelphia, PA, ⁷Exagen, Vista, CA
Background/Purpose: Novel autoantibodies (Ab) capable of identifying unique subgroups of seronegative rheumatoid arthritis (SN-RA) while providing specificity for RA comparable to ACPA reflects an opportunity…
Abstract Number: 2667 • ACR Convergence 2024
Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein
Jon Musai¹, Sahana Jayaraman², katherine Pak³, Iago Pinal-Fernandez⁴, Sandra Muñoz-braceras⁵, Maria Casal-Dominguez⁶, Eric Cho⁵, Fa'alataitaua Fitisemanu⁵, jose milisenda⁷, Lisa Rider⁸, Adam Schiffenbauer³, Albert Selva-O’Callaghan⁹, Thomas E Lloyd¹⁰, Lisa Christopher-Stine¹¹, Peter Burbelo¹², Benjamin Larman¹¹ and Andrew Mammen¹³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³National Institutes of Health, Bethesda, MD, ⁴NIAMS/National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁶NIAMS, NIH, Bethesda, MD, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIEHS, NIH, Garrett Park, MD, ⁹Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ¹⁰Johns Hopkins University School of Medicine, Lutherville, MD, ¹¹Johns Hopkins University, Baltimore, MD, ¹²National Institute of Dental and Craniofacial Research, Bethesda, MD, ¹³NIH, Bethesda, MD
Background/Purpose: Many myositis patients have myositis-specific autoantibodies (MSA) that define unique clinical phenotypes. For instance, dermatomyositis (DM) patients with anti-Mi2 autoantibodies have weaker muscles, higher…
Abstract Number: 0151 • ACR Convergence 2024
Immunoproteomic Profiling of Antibodies in Autoimmune Diseases
Choa Yun¹, Ji Qiu², M. Constanza Camargo³, Lusheng Song², Joshua LaBaer², Hyokyoung G. Hong³, Eric A. Engels³, Maddy Edie-Booker⁴, Adam Schiffenbauer⁵, Lisa Rider⁶, Frederick Miller⁷, Sarfaraz Hasni⁵, Blake M. Warner⁵, Mārcis Leja⁸ and Minkyo Song⁹, ¹National Institute on Aging, Rockville, MD, ²Arizona State University, Tempe, ³National Cancer Institute, Rockville, ⁴National Institute on Aging, Baltimore, MD, ⁵NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, ⁶NIEHS, NIH, Garrett Park, MD, ⁷NIH, NIEHS, Chapel Hill, NC, ⁸University of Latvia, Rīga, Latvia, ⁹National Institutes on Aging, Baltimore, MD
Background/Purpose: Prior research has investigated a limited range of candidate markers within individual autoimmune diseases. This study aimed to identify specific and common autoantibodies and…
Abstract Number: 0627 • ACR Convergence 2024
Clinical Conditions Associated with Presence of a High-titer Antinuclear Antibody in Individuals Without Autoimmune Disease
Matthew Chung¹, John Shelley², John Still², Gul Karakoc³, Xiaodi Ruan⁴, Jonathan D. Mosley⁴, C. Michael Stein⁴ and Vivian K. Kawai⁴, ¹VU, Nashville, TN, ²VUMC, Nashville, TN, ³Vanderbilt University Medical Center, Mt. Pleasant, SC, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that are commonly present in SLE and other autoimmune (AI) disorders. However, a positive ANA…
Abstract Number: 1146 • ACR Convergence 2024
Impact of COVID-19 on Myositis Testing Trends
Angel Kevin Garza-Elizondo¹, Rosa Icela Arvizu-Rivera², Pablo Gamez-Siller³, Daniela Alejandra Salcedo-Soto⁴, Jesus Cardenas-de la Garza⁵, Gisela Garcia-Arellano⁶, Miguel Angel Villarreal-Alarcon² and Dionicio Galarza-Delgado⁷, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM), also known as myositis, are a group of heterogeneous autoimmune disorders that lead to muscle injury. Autoantibodies help make the…
Abstract Number: 1561 • ACR Convergence 2024
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…
Abstract Number: 1788 • ACR Convergence 2024
Memory B Cell Activation and Dysregulation in Systemic Lupus Erythematosus
Shady Younis¹, Salvinaz Moutusy², Shaghayegh Jahanbani², Xiaohao Wu², Marlayna Harris², Mahesh Pandit³, Laura van Dam⁴, orr Sharpe⁵, Paul Utz¹ and William Robinson⁶, ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Stanford, ³Stanford University School of Medicine, Stanofrd, ⁴Stanford, Palo Alto, CA, ⁵Department of Immunology and Rheumatology, Stanford University, Stanford, CA, ⁶Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA
Background/Purpose: B cell dysregulation and production of autoantibodies against autoantigens are hallmarks of Systemic lupus erythematosus (SLE). In healthy adults (HC), B cells with autoreactive…

« Previous Page
1
…
4
5
6
7
8
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].